Myeloid growth factors: Clinical practice guidelines in oncology™ Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Colony-Stimulating Factors
  • Neutropenia

abstract

  • Chemotherapy-induced neutropenia can cause complications that result in dose reductions or treatment delays that can, in turn, compromise clinical outcomes. Although the prophylactic use of colony-stimulating factors (CSFs) can reduce the risk, severity, and duration of severe and febrile neutropenia, they are not routinely administered to all patients undergoing myelosuppressive chemotherapy because of the costs. Selective use may, however, enhance their cost-effectiveness. These guidelines discuss the preventative or prophylactic use of recombinant human granulocyte-CSF to reduce the incidence, length, and severity of chemotherapy-related neutropenia and and prevent life-threatening complications. © Journal of the National Comprehensive Cancer Network.

publication date

  • February 2007

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 17335688

Additional Document Info

start page

  • 188

end page

  • 202

volume

  • 5

number

  • 2